Dyne Therapeutics (NASDAQ:DYN) Hits New 12-Month Low – Time to Sell?

Dyne Therapeutics, Inc. (NASDAQ:DYN) shares reached a new 52-week low during trading on Wednesday . The company traded as low as $11.62 and last traded at $11.89, with a volume of 3031714 shares changing hands. The stock had previously closed at $12.32.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the company. Chardan Capital restated a “buy” rating and set a $50.00 price target on shares of Dyne Therapeutics in a research note on Friday, February 28th. HC Wainwright decreased their price target on Dyne Therapeutics from $55.00 to $46.00 and set a “buy” rating on the stock in a research note on Friday, February 28th. Raymond James raised Dyne Therapeutics to a “strong-buy” rating in a research report on Thursday, December 12th. Robert W. Baird started coverage on Dyne Therapeutics in a research report on Friday, December 13th. They set an “outperform” rating and a $46.00 price objective on the stock. Finally, Guggenheim reaffirmed a “buy” rating on shares of Dyne Therapeutics in a research report on Friday, January 24th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $48.64.

Dyne Therapeutics Price Performance

The firm has a market cap of $1.21 billion, a price-to-earnings ratio of -3.34 and a beta of 1.11. The firm’s 50 day moving average price is $16.75 and its two-hundred day moving average price is $27.26.

Dyne Therapeutics (NASDAQ:DYN) last issued its earnings results on Tuesday, March 4th. The company reported ($0.88) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.04. On average, analysts anticipate that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current year.

Insider Buying and Selling at Dyne Therapeutics

In other news, insider Oxana Beskrovnaya sold 2,598 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $13.95, for a total transaction of $36,242.10. Following the completion of the transaction, the insider now directly owns 199,087 shares of the company’s stock, valued at $2,777,263.65. This trade represents a 1.29 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Richard William Scalzo sold 1,455 shares of the firm’s stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $28.12, for a total transaction of $40,914.60. Following the transaction, the senior vice president now directly owns 127,078 shares of the company’s stock, valued at approximately $3,573,433.36. This trade represents a 1.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 6,387 shares of company stock valued at $142,789. Corporate insiders own 20.77% of the company’s stock.

Hedge Funds Weigh In On Dyne Therapeutics

A number of hedge funds have recently made changes to their positions in DYN. FMR LLC lifted its holdings in shares of Dyne Therapeutics by 69.7% during the 3rd quarter. FMR LLC now owns 9,026,697 shares of the company’s stock valued at $324,239,000 after acquiring an additional 3,707,734 shares in the last quarter. Janus Henderson Group PLC increased its stake in Dyne Therapeutics by 47.3% during the 3rd quarter. Janus Henderson Group PLC now owns 6,813,163 shares of the company’s stock worth $244,755,000 after buying an additional 2,189,339 shares during the period. Jefferies Financial Group Inc. purchased a new stake in Dyne Therapeutics during the 4th quarter worth $42,408,000. Norges Bank bought a new stake in shares of Dyne Therapeutics in the 4th quarter worth about $22,384,000. Finally, Point72 Asset Management L.P. increased its position in shares of Dyne Therapeutics by 802.3% in the 4th quarter. Point72 Asset Management L.P. now owns 924,681 shares of the company’s stock worth $21,785,000 after purchasing an additional 822,201 shares during the last quarter. Institutional investors and hedge funds own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.